<DOC>
	<DOCNO>NCT02019758</DOCNO>
	<brief_summary>Purpose : To determine whether oral viscous budesonide ( OVB ) fluticasone meter dose inhaler ( MDI ) effectively treat EoE improve histologic finding symptom , medication provide durable treatment response , whether biomarkers predict treatment response . Participants : A total 122 16-80 year old patient new diagnosis eosinophilic esophagitis ( EoE ) refer upper endoscopy . Procedures : This prospective , randomize , double-blind , double-dummy , clinical trial compare OVB fluticasone MDI treatment EoE . This overall study design generate data three Aims</brief_summary>
	<brief_title>Budesonide Versus Fluticasone Treatment Eosinophilic Esophagitis</brief_title>
	<detailed_description>This prospective , randomize , double-blind , double-dummy , clinical trial compare oral viscous budesonide ( OVB ) fluticasone meter dose inhaler ( MDI ) treatment EoE . A total 122 subject age 16-80 year old randomize 1:1 fashion one two active treatment arm : OVB + placebo inhaler fluticasone MDI + placebo slurry . In first arm , subject treat OVB dose 1 mg twice daily , also instruct use placebo inhaler identical fluticasone MDI , instruction swallow 4 puff twice daily . The OVB slurry equivalent use clinically : 1 mg/4 mL aqueous budesonide mix 10 g sucralose . Rather ask subject mix slurry risk inconsistent formulation , UNC investigational drug pharmacy ( IDP ) provide pre-mixed OVB patient . The IDP also provide placebo inhaler patient . The dose OVB chosen commonly study dose , include one prior study lead Principal Investigator , accurately estimate response rate . In second arm , subject treat fluticasone MDI dose 880 mcg twice daily ( 4 puff 220 mcg inhaler twice daily ) , also instruct take 4 mL twice daily placebo slurry sucralose identical consistency taste OVB . The UNC investigational drug pharmacy ( IDP ) provide fluticasone MDIs pre-mixed placebo slurry patient . The dose fluticasone MDI chosen commonly use dose adolescent adult EoE , effect estimate also available . For arm , slurry administer first , MDI administer 15 minute later , patient take nothing mouth additional 30 minute . Subjects receive 8 week treatment monitor 52 week recurrence symptom .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criterion follow : Age : 16 80 year Subject clinically indicate endoscopy suspicious EoE BID PPI least 8 week OR New diagnosis EoE per consensus guideline . Cases must symptoms dysphagia , persistent esophageal eosinophilia ( â‰¥ 15 eosinophil least one highpower field ) 8 week treatment twice daily protonpump inhibitor , compete cause esophageal eosinophilia exclude . Exclusion criterion follow : Medical instability precludes safely perform upper endoscopy Ongoing recent symptom intestinal bleeding ( throw blood , pass blood stool ) Concomitant eosinophilic gastroenteritis Esophageal narrow stricturing allow standard 9 mm upper endoscopy scope pas Cancer esophagus , stomach , intestine Previous esophageal surgery Esophageal varix ( dilate blood vessel esophagus ) Current use blood thinner like Plavix Coumadin stop prior endoscopy procedure Any corticosteroid exposure within 4 week prior baseline endoscopic exam . Exclusionary corticosteroid exposure define swallowed topical steroid EoE systemic steroid condition within four week prior baseline endoscopy . Corticosteroids use asthma intranasal corticosteroid exclusion allowable . Pregnancy Inability read understand English</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>